XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 20,690 $ 9,981
Available-for-sale investments 93,695 56,165
Other receivables 1,625 11,775
Prepaid expenses 3,437 2,950
Total current assets 119,447 80,871
Restricted cash 3,190 3,165
Property and equipment, net 5,167 3,059
Operating lease, right-of-use assets 6,942 7,250
Financing lease, right-of-use assets 1,948 1,248
Other assets 144 193
Total assets 136,838 95,786
Current liabilities:    
Accounts payable 3,965 3,106
Accrued expenses 8,888 9,862
Current portion of operating lease liability 381 630
Current portion of financing lease liability 420 264
Total current liabilities 13,654 13,862
Long-term operating lease liability, net of current portion 11,916 9,633
Long-term financing lease liability, net of current portion 1,570 1,007
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of March 31, 2023 (unaudited) and December 31, 2022; no shares issued or outstanding as of March 31, 2023 (unaudited) and December 31, 2022
Common stock, $0.001 par value per share; 85,000,000 authorized shares as of March 31, 2023 (unaudited) and December 31, 2022; issued and outstanding shares - 53,339,611 as of March 31, 2023 (unaudited) and 29,498,488 as of December 31, 2022 53 29
Additional paid-in capital 539,659 489,502
Accumulated other comprehensive loss (248) (433)
Accumulated deficit (429,585) (417,634)
Total aTyr Pharma stockholders’ equity 109,879 71,464
Noncontrolling interest in Pangu BioPharma Limited (181) (180)
Total stockholders' equity 109,698 71,284
Total liabilities and stockholders’ equity $ 136,838 $ 95,786